Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.

Conditions

Non-Small Cell Lung Cancer
Triple-negative Breast Cancer

Interventions

BIOLOGICAL: PF-06936308

Sponsor

Pfizer